High-dose intravenous methylprednisolone for hantavirus cardiopulmonary syndrome in Chile: A double-blind, randomized controlled clinical trial

Clinical Infectious Diseases

Volumn 57, Issue 7, 2013, Pages 943-951

  Vial, Pablo A ^a   Valdivieso, Francisca ^a   Ferres, Marcela ^b   Riquelme, Raul ^c   Rioseco, M Luisa ^c   Calvo, Mario ^c   Castillo, Constanza ^d   Díaz, Ricardo ^e   Scholz, Luis ^f   Cuiza, Analia ^a   Belmar, Edith ^a   Hernandez, Carla ^a   Martinez, Jessica ^a   Lee, Sang Joon ^g   Mertz, Gregory J ^g  

^a UNIVERSIDAD DEL DESARROLLO   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

^d UNIVERSIDAD DE LA FRONTERA   (Chile)

^e Hospital Base de Los Ángeles   (United States)

^f Hospital Regional de Osorno   (Chile)

^g UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

Clinical trial; Hantavirus; Hantavirus cardiopulmonary syndrome; Hantavirus pulmonary syndrome; Methylprednisolone

Indexed keywords

IMMUNOGLOBULIN M; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; PLACEBO; VIRUS RNA;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; ANDES VIRUS; ANTIBODY DETECTION; ARTERIAL OXYGEN TENSION; ARTICLE; CHILE; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HANTAVIRUS; HANTAVIRUS PULMONARY SYNDROME; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS DIAGNOSIS; VIRUS LOAD;

CLINICAL TRIAL; HANTAVIRUS; HANTAVIRUS CARDIOPULMONARY SYNDROME; HANTAVIRUS PULMONARY SYNDROME; METHYLPREDNISOLONE;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; CHILE; DOUBLE-BLIND METHOD; FEMALE; HANTAVIRUS; HANTAVIRUS PULMONARY SYNDROME; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; METHYLPREDNISOLONE; MIDDLE AGED; RNA, VIRAL; TREATMENT OUTCOME;

EID: 84884377717     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit394     Document Type: Article

References (36)

1. Schmaljohn C, Hjelle B. Hantaviruses: a global disease problem. Emerg Infect Dis 1997; 3:95-104.
2. Gajdusek DC. Virus hemorrhagic fevers. Special reference to hemorrhagic fever with renal syndrome (epidemic hemorrhagic fever). J Pediatr 1962; 60:841-57.
3. Smadel JE. Epidemic hemorrhagic fever. Am J Public Health Nations Health 1953; 43:1327-30.
4. Nichol ST, Spiropoulou CF, Morzunov S, et al. Genetic identification of a hantavirus associated with an outbreak of acute respiratory illness. Science 1993; 262:914-7.
5. Ksiazek TG, Peters CJ, Rollin PE, et al. Identification of a new North American hantavirus that causes acute pulmonary insufficiency. Am J Trop Med Hyg 1995; 52:117-23.
6. Lopez N, Padula P, Rossi C, Lazaro ME, Franze-Fernandez MT. Genetic identification of a new hantavirus causing severe pulmonary syndrome in Argentina. Virology 1996; 220:223-6.
7. Lee HW, Lee PW, Johnson KM. Isolation of the etiologic agent of Korean hemorrhagic fever. J Infect Dis 1978; 137:298-308.
8. Medina RA, Torres-Perez F, Galeno H, et al. Ecology, genetic diversity, and phylogeographic structure of Andes virus in humans and rodents in Chile. J Virol 2009; 83:2446-59.
9. Martinez VP, Bellomo C, San Juan J, et al. Person-to-person transmission of Andes virus. Emerg Infect Dis 2005; 11:1848-53.
10. Padula PJ, Edelstein A, Miguel SD, Lopez NM, Rossi CM, Rabinovich RD. Hantavirus pulmonary syndrome outbreak in Argentina: molecular evidence for person-to-person transmission of Andes virus. Virology 1998; 241:323-30.
11. Ferres M, Vial P, Marco C, et al. Prospective evaluation of household contacts of persons with hantavirus cardiopulmonary syndrome in Chile. J Infect Dis 2007; 195:1563-71.
12. Ministerio de Salud de Chile. Departamento de Epidemiologia,Vigilancia Hantavirus. Available at: http://epi.minsal.cl/vigilancia-epidemiol ogica/enfermedades-de-notificacion-obligatoria/vigilancia-hantavirus/. Accessed 20 January 2012.
13. Mertz GJ, Hjelle B, Crowley M, Iwamoto G, Tomicic V, Vial PA. Diagnosis and treatment of new world hantavirus infections. Curr Opin Infect Dis 2006; 19:437-42.
14. Jonsson CB, Hooper J, Mertz G. Treatment of hantavirus pulmonary syndrome. Antiviral Res 2008; 78:162-9.
15. Severson WE, Schmaljohn CS, Javadian A, Jonsson CB. Ribavirin causes error catastrophe during Hantaan virus replication. J Virol 2003; 77:481-8.
16. Huggins JW, Kim GR, Brand OM, McKee KT Jr. Ribavirin therapy for Hantaan virus infection in suckling mice. J Infect Dis 1986; 153: 489-97.
17. Huggins JW, Hsiang CM, Cosgriff TM, et al. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis 1991; 164:1119-27.
18. Mertz GJ, Miedzinski L, Goade D, et al. Placebo-controlled, doubleblind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clin Infect Dis 2004; 39:1307-13.
19. Zaki SR, Greer PW, Coffield LM, et al. Hantavirus pulmonary syndrome. Pathogenesis of an emerging infectious disease. Am J Pathol 1995; 146:552-79.
20. Nolte KB, Feddersen RM, Foucar K, et al. Hantavirus pulmonary syndrome in the United States: a pathological description of a disease caused by a new agent. Hum Pathol 1995; 26:110-20.
21. Mori M, Rothman AL, Kurane I, et al. High levels of cytokine-producing cells in the lung tissues of patients with fatal hantavirus pulmonary syndrome. J Infect Dis 1999; 179:295-302.
22. Ennis FA, Cruz J, Spiropoulou CF, et al. Hantavirus pulmonary syndrome: CD8+ and CD4+ cytotoxic T lymphocytes to epitopes on Sin Nombre virus nucleocapsid protein isolated during acute illness. Virology 1997; 238:380-90.
23. Kilpatrick ED, Terajima M, Koster FT, Catalina MD, Cruz J, Ennis FA. Role of specific CD8+ T cells in the severity of a fulminant zoonotic viral hemorrhagic fever, hantavirus pulmonary syndrome. J Immunol 2004; 172:3297-304.
24. Sayer WJ, Entwhisle G, Uyeno B, Bignall RC. Cortisone therapy of early epidemic hemorrhagic fever: a preliminary report. Ann Intern Med 1955; 42:839-51.
25. Tapia M, Mansilla C, Vera J. Síndrome pulmonar por hantavirus: experiencia clínica en diagnóstico y tratamiento. Hospital Coyhaique-Chile. Rev Chil Infect 2000; 17:258-69.
26. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010; 152:726-32.
27. Padula PJ, Rossi CM, Della Valle MO, et al. Development and evaluation of a solid-phase enzyme immunoassay based on Andes hantavirus recombinant nucleoprotein. J Med Microbiol 2000; 49:149-55.
28. Kramski M, Meisel H, Klempa B, Kruger DH, Pauli G, Nitsche A. Detection and typing of human pathogenic hantaviruses by real-time reverse transcription-PCR and pyrosequencing. Clin Chem 2007; 53:1899-905.
29. Schafer P, Braun RW, Mohring K, et al. Quantitative determination of human cytomegalovirus target sequences in peripheral blood leukocytes by nested polymerase chain reaction and temperature gradient gel electrophoresis. J Gen Virol 1993; 74(Pt 12):2699-707.
30. Hammerbeck CD, Hooper JW. T cells are not required for pathogenesis in the Syrian hamster model of hantavirus pulmonary syndrome. J Virol 2011; 85:9929-44.
31. Steinberg KP, Hudson LD, Goodman RB, et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006; 354:1671-84.
32. Bharadwaj M, Nofchissey R, Goade D, Koster F, Hjelle B. Humoral immune responses in the hantavirus cardiopulmonary syndrome. J Infect Dis 2000; 182:43-8.
33. Manigold T, Martinez J, Lazcano X, et al. Case report: T-cell responses during clearance of Andes virus from blood cells 2 months after severe hantavirus cardiopulmonary syndrome. J Med Virol 2008; 80:1947-51.
34. Terajima M, Hendershot JD 3rd, Kariwa H, et al. High levels of viremia in patients with the hantavirus pulmonary syndrome. J Infect Dis 1999; 180:2030-4.
35. Xiao R, Yang S, Koster F, Ye C, Stidley C, Hjelle B. Sin Nombre viral RNA load in patients with hantavirus cardiopulmonary syndrome. J Infect Dis 2006; 194:1403-9.
36. Wernly JA, Dietl CA, Tabe CE, et al. Extracorporeal membrane oxygenation support improves survival of patients with hantavirus cardiopulmonary syndrome refractory to medical treatment. Eur J Cardiothorac Surg 2011; 40:1334-40.